ZYUS Life Sciences Corporation ZYUS.V
TSX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -21.77% | -13.50% | -17.49% | 0.00% | 9.62% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -21.77% | -13.50% | -17.49% | 0.00% | 9.62% |
| Cost of Revenue | -69.60% | -69.74% | -70.94% | -38.98% | -42.13% |
| Gross Profit | 93.99% | 98.26% | 98.50% | 48.14% | 53.37% |
| SG&A Expenses | -11.50% | -12.47% | -12.02% | -28.97% | -32.41% |
| Depreciation & Amortization | -40.86% | -24.52% | -9.76% | -5.96% | -7.40% |
| Other Operating Expenses | -78.12% | -72.31% | -44.63% | 0.25% | 5.95% |
| Total Operating Expenses | -25.23% | -17.75% | -11.56% | -23.68% | -21.45% |
| Operating Income | 25.34% | 17.87% | 11.38% | 24.24% | 22.14% |
| Income Before Tax | 45.63% | 42.51% | 39.88% | 17.93% | 17.79% |
| Income Tax Expenses | -- | -- | -- | 66.11% | 65.84% |
| Earnings from Continuing Operations | 42.36% | 39.07% | 36.20% | 10.23% | 10.17% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 42.36% | 39.07% | 36.20% | 10.23% | 10.17% |
| EBIT | 25.34% | 17.87% | 11.38% | 24.24% | 22.14% |
| EBITDA | 21.32% | 16.16% | 11.68% | 26.74% | 24.06% |
| EPS Basic | 46.04% | 42.74% | 39.60% | 15.53% | 15.07% |
| Normalized Basic EPS | 17.42% | 12.41% | 5.99% | 29.75% | 28.56% |
| EPS Diluted | 44.59% | 41.57% | 39.23% | 15.75% | 15.93% |
| Normalized Diluted EPS | 17.42% | 12.41% | 5.99% | 29.75% | 28.56% |
| Average Basic Shares Outstanding | 7.20% | 7.27% | 6.58% | 6.47% | 5.32% |
| Average Diluted Shares Outstanding | 7.20% | 7.27% | 6.58% | 6.47% | 5.32% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |